可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 卢春燕,余敏,曾智. B型利钠尿肽及其在临床中的应用[J]. 心脏杂志, 2003, 15(2):172-174.
[2] 史小敏,徐国宾,夏铁安. B型利尿钠肽的生物学特性及其测定的临床应用[J]. 临床检验杂志, 2005, 23(1):67-70
[3] 胡刘华,单培仁,何奔. 钠尿肽抗心衰治疗的研究进展[J]. 心脏杂志, 2008, 20(5):644-648.
[4] 丁嵩,何奔. 脑钠尿肽在急性冠脉综合征的应用进展[J]. 心脏杂志, 2006, 18(1):103-105.
[5] 丁嵩,何奔,卜军,等. 急性冠脉综合征TIMI风险积分与脑钠尿肽及临床预后的关系[J]. 心脏杂志, 2006, 18(4):417-421.
[6] Tschpe C, Kasner M, Westermann D, et al. The role of NTproBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements[J]. Eur Heart J, 2005, 26(21):2277-2284.
[7] Iwanaga Y, Nishi I, Furuichi S, et al. BType natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure[J]. J Am Coll Cardiol, 2006, 47 (4):742-748.
[8] Vanderheyden M, Goethals M, Verstreken S, et al.Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy[J]. J Am Coll Cardiol, 2004, 44(12):2349- 2354.
[9] Watanabe S, Shite J, Takaoka H, et al. Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure[J]. Eur Heart J, 2006, 27(7):832-838.